Serum YKL-40 as a biomarker for liver fibrosis in chronic hepatitis B patients with normal and mildly elevated ALT.

about

Serum YKL-40 as a biomarker for liver fibrosis in chronic hepatitis B patients with normal and mildly elevated ALT.

Item

http://www.wikidata.org/entity/Q52619982

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Serum YKL-40 as a biomarker fo ...... ormal and mildly elevated ALT.

@en

Serum YKL-40 as a biomarker fo ...... ormal and mildly elevated ALT.

@nl

type

Item

label

Serum YKL-40 as a biomarker fo ...... ormal and mildly elevated ALT.

@en

Serum YKL-40 as a biomarker fo ...... ormal and mildly elevated ALT.

@nl

prefLabel

Serum YKL-40 as a biomarker fo ...... ormal and mildly elevated ALT.

@en

Serum YKL-40 as a biomarker fo ...... ormal and mildly elevated ALT.

@nl

P1476

Serum YKL-40 as a biomarker fo ...... normal and mildly elevated ALT

@en

P2093

China HepB-Related Fibrosis Assessment Research Group

http://www.w3.org/2001/XMLSchema#string

Guiqiang Wang

http://www.w3.org/2001/XMLSchema#string

Hong Zhao

http://www.w3.org/2001/XMLSchema#string

Linlin Yan

http://www.w3.org/2001/XMLSchema#string

Yongqiong Deng

http://www.w3.org/2001/XMLSchema#string

P2860

Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family

The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways

Chronic hepatitis B: update 2009

Histological grading and staging of chronic hepatitis

Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.

Hepatic stellate cells and liver fibrosis.

AASLD guidelines for treatment of chronic hepatitis B.

Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease.

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update.

Noninvasive measures of liver fibrosis.

P2888

s15010-018-1136-2

P304

385-393

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S15010-018-1136-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jiyuan Zhou

P577

2018-03-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29600444

http://www.w3.org/2001/XMLSchema#string

P932

5976691

http://www.w3.org/2001/XMLSchema#string